RLMD
Relmada Therapeutics Inc
NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY
$7.36
-0.32% today
Updated 2026-06-04
Market cap
$657.66M
P/E ratio
—
P/S ratio
9,001.90x
EPS (TTM)
$-1.09
Dividend yield
—
52W range
$1 – $8
Volume
1.2M
Relmada Therapeutics Inc (RLMD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7941.00 | $5129.00 | — | — | — | — | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -35.4% | -100.0% | — | — | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $5799.00 | $4036.00 | — | $9256.00 | $54819.00 | $85271.00 | $2627.00 | $4870.00 | $3752.00 | $1258.00 | — | — | — | — |
| Gross profit | $2142.00 | $1093.00 | — | $-9256.00 | $-54819.00 | $-85271.00 | $-2627.00 | $-4870.00 | $-3752.00 | $-1258.00 | — | — | — | — |
| Gross margin | 27.0% | 21.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | — | $5.38M | $7.87M | $7.87M | $6.21M | $1.29M | $2.94M | $7.86M | $35.97M | $90.62M | $113.32M | $54.81M | $46.18M | $744560.00 |
| SG&A | $9090.00 | $45076.00 | $9.23M | $9.23M | $10.01M | $5.93M | $3.98M | $7.25M | $24.87M | $35.08M | $47.93M | $48.90M | $37.72M | $311904.00 |
| Operating income | $-12052.00 | $-45015.00 | $-17.10M | $-17.10M | $-16.22M | $-7.22M | $-6.92M | $-15.11M | $-60.84M | $-125.70M | $-161.25M | $-103.70M | $-83.89M | $-59.10M |
| Operating margin | -151.8% | -877.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $-11675.00 | $-45015.00 | $-20.79M | $-17.09M | $-16.03M | $-6.92M | $-6.92M | $-15.11M | $-59.33M | $-125.70M | $-161.25M | $4.91M | $-83.89M | $-59.10M |
| EBITDA margin | -147.0% | -877.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | $-12429.00 | $-45388.00 | $-20.80M | $-17.10M | $-16.08M | $-7.01M | $-6.92M | $-15.11M | $-59.34M | $-125.70M | $-161.25M | $-98.79M | $-79.98M | — |
| Interest expense | — | — | $4922.00 | $4922.00 | — | $550.00 | $1.34M | — | $1.40M | $48317.00 | $4.21M | — | — | — |
| Income tax | $-377.00 | $-9.58M | — | $3.70M | $-13.11M | $-716000.00 | $2.05M | $4.59M | $-1.38M | $48317.00 | $-2.66M | $-103702.00 | — | — |
| Effective tax rate | 3.0% | 99.5% | 0.0% | -21.7% | 81.5% | 10.2% | -29.6% | -44.1% | 2.3% | -0.0% | 1.7% | 0.1% | 0.0% | 0.0% |
| Net income | $-12052.00 | $-45015.00 | $-20.80M | $-20.80M | $-2.98M | $-6.29M | $-8.96M | $-15.01M | $-59.46M | $-125.75M | $-157.04M | $-98.79M | $-79.98M | $-57.39M |
| Net income growth (YoY) | — | -273.5% | -46114.8% | -0.0% | +85.7% | -111.3% | -42.5% | -67.4% | -296.2% | -111.5% | -24.9% | +37.1% | +19.0% | +28.3% |
| Profit margin | -151.8% | -877.7% | — | — | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
How much free cash flow does RLMD generate?
RLMD produced $-45.79M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is RLMD's balance sheet healthy?
RLMD holds $3.50M in cash and equivalents against — in long-term debt, on $86.51M of shareholder equity. That debt is best read against the cash flow the business throws off each year.